INTEGRATED BIOPHARMA INC Quarterly Deferred Federal Income Tax Expense (Benefit) in USD from Q3 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Integrated Biopharma Inc quarterly/annual Deferred Federal Income Tax Expense (Benefit) history and growth rate from Q3 2020 to Q3 2024.
  • Integrated Biopharma Inc Deferred Federal Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $190K, a 3067% increase year-over-year.
  • Integrated Biopharma Inc Deferred Federal Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $308K, a 211% increase year-over-year.
  • Integrated Biopharma Inc annual Deferred Federal Income Tax Expense (Benefit) for 2024 was $124K, a 125% increase from 2023.
Deferred Federal Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Federal Income Tax Expense (Benefit), Quarterly (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $308K $190K +$184K +3067% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $124K $113K +$25K +28.4% Apr 1, 2024 Jun 30, 2024 10-K 2024-09-20
Q1 2024 $99K $81K +$72K +800% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $27K -$76K -$72K -1800% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-12
Q3 2023 $99K $6K +$44K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $55K $88K Apr 1, 2023 Jun 30, 2023 10-K 2024-09-20
Q1 2023 $9K +$115K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$4K +$440K +99.1% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 -$38K $0 0% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q1 2022 -$106K +$295K +73.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$444K -$696K -276% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-10
Q3 2021 -$38K -$311K -114% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q1 2021 -$401K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $252K Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 $273K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.